Hvivo reports record-high H1 2024 revenue of £35.6m, up 30%, with Canary Wharf facility fully operational and on track for full-year guidance.
Hvivo, a Dublin and London-listed pharmaceutical services company, reported a record-high revenue of £35.6m in H1 2024, up 30% from the previous year's £27.3m. The company's Canary Wharf quarantine facility, offering capacity for future growth, is now fully operational. Hvivo is on track to meet its full-year revenue guidance of £62m and maintain ebitda margins at the upper end of market expectations.
July 17, 2024
6 Articles